Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Antipsychotic-Induced Weight Gain.
Sarah Pascale, Justin P Reinert
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed the efficacy and safety of GLP-1 receptor agonists for antipsychotic-induced weight gain. Six studies were reviewed, with four trials contributing to the meta-analysis. Compared with placebo, GLP-1 agonists were associated with a weight difference of -5.85 kg (P = 0.0622, 95% CI = -9.72 to -1.97); the efficacy endpoints did not reach statistical significance. Gastrointestinal adverse effects were more frequent, with a risk ratio of 1.83 (95% CI = 1.42 to 2.37).
Key findings
- The weight difference versus placebo was -5.85 kg (P = 0.0622, 95% CI = -9.72 to -1.97), not statistically significant.
- BMI changed by -2.11 kg/m 2 (P = 0.7692, 95% CI = -5.51 to 1.29) versus placebo.
- HbA 1c changed by -1.58 (P = 0.6659, 95% CI = -4.75 to 1.58) versus placebo.
- The risk ratio for gastrointestinal adverse effects with GLP-1 agonists versus placebo was 1.83 (95% CI = 1.42 to 2.37).
Why it matters
Antipsychotic-associated weight gain can complicate ongoing treatment, and the review examines a potential pharmacologic approach to this problem. The findings suggest possible weight reduction, but the efficacy estimates did not reach statistical significance, while gastrointestinal adverse effects were more common. These results help frame the balance of potential benefit and harm when considering this drug class in this context.
What to keep in mind
Only six studies were included, and four contributed to the meta-analysis; the reported efficacy endpoints did not reach statistical significance.